Prospector
Profile
08.0001
|
| |
| Amazon Biotech, Inc. |
NAICS |
541710 |
| 43 West 33rd Street, Suite 405
New York, NY 10001 |
Description |
Biotechnology |
| (212) 947-3362 |
Employees |
6 |
| http://www.amazonbiotech.com/ |
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-1.6400 |
| |
Assets |
(mil) |
0.2000 |
| |
Liability |
(mil) |
1.1300 |
| |
(for the year ended 2007-07-31) |
| |
|
Category:
Audit Concerns
|
| |
|
Event:
Meyler & Company LLC notes that Amazon Biotech, Inc. has incurred net losses since inception of $14,131,734, has a stockholders' deficit of $927,663 as of July 31, 2007, and has no significant assets at July 31, 2007. The Company anticipates generating losses for the next 12 months. Therefore, the auditor concludes that the Company may be unable to continue operations in the future as a going concern.
|
| |
|
Intellectual Property:
The Company intends to protect the intellectual property rights of its products by obtaining patents. The Company was granted a US patent (#7160561 issued Jan 2007) on a Herbal Composition and Method of Treating HIV Infection. [SEC Filing 10-KSB 11-28-07]
|
| |
|
Description:
The Company engages in the research and development of natural drugs in the United States.
|
| |
|
Officers:
Mechael Kanovsky (Pres. & Dir.); Simcha Edell (CFO & Dir.)
|
| |
|
Auditor:
Meyler & Company LLC
|
| |
|
Securities:
Common Stock-Symbol AMZO.OB; OTC BB;
17,096,579 common shares outstanding as of November 26, 2007.
|
| |
| |
| |
| return to main page |
